Johnson & Johnson completes $1 billion acquisition of Firefly Bio
- Johnson & Johnson acquired Firefly Bio for $1 billion in cash.
- Firefly Bio’s Firelink™ degrader antibody conjugate (DAC) platform is designed to deliver selective protein degraders to cancer cells and target pan‑KRAS and other drivers of hard‑to‑treat solid tumours.
- The transaction is being accounted for as an asset acquisition, triggering an in‑process research and development charge of approximately $1 billion in Q3 2026.
- Johnson & Johnson expects the deal to dilute adjusted operational EPS and adjusted EPS by about $0.46 in 2026 and $0.08 in 2027.
Deal overview
Johnson & Johnson has completed its acquisition of Firefly Bio for $1 billion in cash. The transaction will be accounted for as an asset acquisition.
Technology and strategic rationale
Firefly Bio’s Firelink™ degrader antibody conjugate (DAC) platform aims to deliver highly selective protein degraders directly to cancer cells while preserving healthy tissue. Johnson & Johnson says the platform broadens its next‑generation antibody engineering capabilities and expands its oncology portfolio to address difficult‑to‑treat solid tumours, including KRAS‑driven cancers.
Financial accounting and near‑term impact
The company expects an in‑process research and development charge of roughly $1 billion in Q3 2026 related to the acquisition. It also projects dilution to adjusted operational earnings per share and adjusted earnings per share of approximately $0.46 in 2026 and $0.08 in 2027.
Integration and outlook
Johnson & Johnson frames the acquisition as strengthening its ability to accelerate development of targeted oncology therapies by combining Firefly Bio’s platform with its antibody engineering and oncology R&D expertise.
Source: J&J